Brovana

Arformoterol
Clinical data


Trade names	Brovana
AHFS/Drugs.com	Monograph
MedlinePlus	a602023
License data	US FDA: Arformoterol
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Inhalation solution for nebuliser
ATC code	none
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	52–65%
Biological half-life	26 hours
Identifiers
IUPAC name N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-1-(4-methoxyphenyl) propan-2-yl]amino]ethyl] phenyl]formamide
CAS Number	67346-49-0^Y
PubChem CID	3083544
IUPHAR/BPS	7479
DrugBank	DB01274^Y
ChemSpider	2340731^Y
UNII	F91H02EBWT
ChEBI	CHEBI:408174^Y
ChEMBL	CHEMBL1201137^N
Chemical and physical data
Formula	C₁₉H₂₄N₂O₄
Molar mass	344.405 g/mol
InChI InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1^Y Key:BPZSYCZIITTYBL-YJYMSZOUSA-N^Y
^NY (what is this?)

Arformoterol is a long-acting β₂ adrenoreceptor agonist (LABA) indicated for the treatment of chronic obstructive pulmonary disease (COPD). It is sold by Sunovion, under the trade name Brovana, as a solution of arformoterol tartrate to be administered twice daily (morning and evening) by nebulization.

It is the active (R,R)-(−)-enantiomer of formoterol and was approved by the United States Food and Drug Administration (FDA) on October 6, 2006 for the treatment of COPD.